The 2014 Canadian cardiovascular society heart failure management guidelines focus update: Anemia, biomarkers, and recent therapeutic trial implications

Canadian Journal of Cardiology

Volumn 31, Issue 1, 2015, Pages 3-16

  Moe, Gordon W ^a   Ezekowitz, Justin A ^b   O'Meara, Eileen ^c   Lepage, Serge ^d   Howlett, Jonathan G ^e   Fremes, Steve ^f   Al Hesayen, Abdul ^a   Heckman, George A ^g   Abrams, Howard ^h   Ducharme, Anique ^c   Estrella Holder, Estrellita ⁱ   Grzeslo, Adam ^j,k   Harkness, Karen ^k   Koshman, Sheri L ^b   McDonald, Michael ^h   McKelvie, Robert ^k   Rajda, Miroslaw ^l   Rao, Vivek ^h   Swiggum, Elizabeth ^m   Virani, Sean ⁿ   Zieroth, Shelley ⁱ   Arnold, J Malcolm O ^o   Ashton, Tom ^p   D'Astous, Michel ^q   Chan, Michael ^r   De, Sabe ^s   Dorian, Paul ^a   Giannetti, Nadia ^t   Haddad, Haissam ^u   Isaac, Debra L ^e   Kouz, Simon ^v,w   Leblanc, Marie Hélène ^x   Liu, Peter ^u   Ross, Heather J ^h   Sussex, Bruce ^y   White, Michel ^c   more..

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MONTREAL HEART INSTITUTE   (Canada)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g UNIVERSITY OF WATERLOO   (Canada)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ ST BONIFACE GENERAL HOSPITAL   (Canada)

^j Joseph Brant Memorial Hospital Burlington   (Canada)

^k MCMASTER UNIVERSITY   (Canada)

^l DALHOUSIE UNIVERSITY   (Canada)

^m ROYAL JUBILEE HOSPITAL   (Canada)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o UNIVERSITY OF WESTERN ONTARIO   (Canada)

^p Penticton   (Canada)

^q UNIVERSITÉ DE MONCTON   (Canada)

^r Edmonton Cardiology Consultants   (Canada)

^s Cape Breton Regional Hospital   (Canada)

^t MCGILL UNIVERSITY   (Canada)

^u UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^v Centre Hospitalier Regional de Lanaudiere   (Canada)

^w UNIVERSITÉ LAVAL   (Canada)

^x LAVAL UNIVERSITY   (Canada)

^y Health Sciences Centre St John's   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; GALECTIN 3; MINERALOCORTICOID ANTAGONIST; NATRIURETIC FACTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PHENYTOIN; RIBAVIRIN; TOLL LIKE RECEPTOR 2; TROPONIN T; ANGIOTENSIN RECEPTOR ANTAGONIST; MEMBRANE METALLOENDOPEPTIDASE;

ANEMIA; ARTICLE; CARDIAC PATIENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG INDICATION; FOLLOW UP; HEALTH CARE MANAGEMENT; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HOSPITAL DISCHARGE; HUMAN; IRON THERAPY; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PRACTICE GUIDELINE; PREVALENCE; PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; CANADA; CARDIOLOGY; ORGANIZATION AND MANAGEMENT;

ANEMIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CANADA; CARDIOLOGY; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NEPRILYSIN; SOCIETIES, MEDICAL;

EID: 84920573564     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.10.022     Document Type: Article

References (92)

1. Arnold J.M., Liu P., Demers C., et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006, 22:23-45.
2. Arnold J.M., Howlett J.G., Dorian P., et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007, 23:21-45.
3. Howlett J.G., McKelvie R.S., Arnold J.M., et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy, and recent important clinical trials. Can J Cardiol 2009, 25:85-105.
4. Howlett J.G., McKelvie R.S., Costigan J., et al. The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Can J Cardiol 2010, 26:185-202.
5. Malcom J., Arnold O., Howlett J.G., et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure-2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol 2008, 24:21-40.
6. McKelvie R.S., Moe G.W., Cheung A., et al. The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol 2011, 27:319-338.
7. McKelvie R.S., Moe G.W., Ezekowitz J.A., et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol 2013, 29:168-181.
8. Moe G.W., Ezekowitz J.A., O'Meara E., et al. The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization. Can J Cardiol 2014, 30:249-263.
9. McCormack J.P., Loewen P. Adding "value" to clinical practice guidelines. Can Fam Physician 2007, 53:1326-1327.
10. Mozaffarian D., Nye R., Levy W.C. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). JAm Coll Cardiol 2003, 41:1933-1939.
11. World Health Organization Vitamin and Mineral Nutrition Information System (VMNIS). Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity 2011, World Health Organization, Geneva.
12. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 2005, 149:391-401.
13. Tang W.H., Yeo P.S. Epidemiology of anemia in heart failure. Heart Fail Clin 2010, 6:271-278.
14. Groenveld H.F., Januzzi J.L., Damman K., et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. JAm Coll Cardiol 2008, 52:818-827.
15. Tang Y.D., Katz S.D. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006, 113:2454-2461.
16. Androne A.S., Katz S.D., Lund L., et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003, 107:226-229.
17. Tang W.H., Tong W., Jain A., et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. JAm Coll Cardiol 2008, 51:569-576.
18. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEngl J Med 2006, 355:251-259.
19. Ather S., Chan W., Bozkurt B., et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. JAm Coll Cardiol 2012, 59:998-1005.
20. Opasich C., Cazzola M., Scelsi L., et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005, 26:2232-2237.
21. Guo L., Wang A.H., Sun Y.L., Lv L., Xu C.E. Serum erythropoietin level predicts the prognosis of chronic heart failure with or without anemia. Exp Ther Med 2013, 6:1327-1331.
22. O'Meara E., Rouleau J.L., White M., et al. Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes. Circ Heart Fail 2014, 7:773-778.
23. van der Meer P., Lipsic E., Westenbrink B.D., et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 2005, 112:1743-1747.
24. Silverberg D.S., Wexler D., Blum M., et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003, 18:141-146.
25. Manjunath S.M., Singh J., Laller K.S. Impact of oral iron therapy on quality of life in patients with heart failure. Int J Basic Clin Pharmacol 2014, 2:43-46.
26. Anker S.D., Comin C.J., Filippatos G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. NEngl J Med 2009, 361:2436-2448.
27. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, etal. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2014; doi:10.1093/eurheartj/ehu385.
28. Avni T., Leibovici L., Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail 2012, 14:423-429.
29. Ghali J.K., Anand I.S., Abraham W.T., et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008, 117:526-535.
30. Swedberg K., Young J.B., Anand I.S., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. NEngl J Med 2013, 368:1210-1219.
31. Arora N.P., Ghali J.K. Anemia and iron deficiency in heart failure. Heart Fail Clin 2014, 10:281-294.
32. Ahamad T., Fiuzat M., Pencina M.J., et al. Charting a roadmap for heart failure biomarker studies. JACC Heart Fail 2014, 2:477-488.
33. Kim H.N., Januzzi J.L. Natriuretic peptide testing in heart failure. Circulation 2011, 123:2015-2019.
34. Maisel A.S., McCord J., Nowak R.M., et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. JAm Coll Cardiol 2003, 41:2010-2017.
35. O'Donoghue M., Chen A., Baggish A.L., et al. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. JCard Fail 2005, 11(5 suppl):S9-14.
36. Bayes-Genis A., Lloyd-Jones D.M., van Kimmenade R.R., et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 2007, 167:400-407.
37. Bazzino O., Fuselli J.J., Botto F., et al. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2004, 25:859-866.
38. Binder L., Pieske B., Olschewski M., et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005, 112:1573-1579.
39. Blyth K.G., Groenning B.A., Mark P.B., et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 2007, 29:737-744.
40. Gerber I.L., Stewart R.A., Legget M.E., et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003, 107:1884-1890.
41. Lindahl B., Lindback J., Jernberg T., et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. JAm Coll Cardiol 2005, 45:533-541.
42. Morello A., Lloyd-Jones D.M., Chae C.U., et al. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J 2007, 153:90-97.
43. Bettencourt P., Azevedo A., Pimenta J., et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004, 110:2168-2174.
44. Cleland J.G., McMurray J.J., Kjekshus J., et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). JAm Coll Cardiol 2009, 54:1850-1859.
45. Januzzi J.L., Sakhuja R., O'Donoghue M., et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006, 166:315-320.
46. Lam L.L., Cameron P.A., Schneider H.G., et al. Meta-analysis: effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting. Ann Intern Med 2010, 153:728-735.
47. Moe G.W., Howlett J., Januzzi J.L., Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007, 115:3103-3110.
48. Mueller C., Laule-Kilian K., Schindler C., et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006, 166:1081-1087.
49. Ezekowitz J.A., Welsh R.C., Gubbels C., et al. Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3). Can J Cardiol 2014, 30:1208-1215.
50. Thomas R., Huntley A., Mann M., et al. Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials. Heart 2013, 99:233-239.
51. Berger R., Moertl D., Peter S., et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. JAm Coll Cardiol 2010, 55:645-653.
52. Eurlings L.W., van Pol P.E., Kok W.E., et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. JAm Coll Cardiol 2010, 56:2090-2100.
53. Januzzi J.L., Rehman S.U., Mohammed A.A., et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. JAm Coll Cardiol 2011, 58:1881-1889.
54. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. JAm Coll Cardiol 2007, 49:1733-1739.
55. Lainchbury J.G., Troughton R.W., Strangman K.M., et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. JAm Coll Cardiol 2009, 55:53-60.
56. Persson H., Erntell H., Eriksson B., et al. Improved pharmacological therapy of chronic heart failure in primary care: a randomized study of NT-proBNP guided management of heart failure-SIGNAL-HF (Swedish Intervention study-Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail 2010, 12:1300-1308.
57. Pfisterer M., Buser P., Rickli H., et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009, 301:383-392.
58. Shah M.R., Califf R.M., Nohria A., et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. JCard Fail 2011, 17:613-621.
59. Troughton R.W., Frampton C.M., Yandle T.G., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000, 355:1126-1130.
60. Braunwald E. Heart failure. JACC Heart Fail 2013, 1:1-20.
61. Troughton R.W., Frampton C.M., Brunner-La Rocca H.P., et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 2014, 35:1559-1567.
62. Felker G.M., Hasselblad V., Hernandez A.F., O'Connor C.M. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422-430.
63. Porapakkham P., Porapakkham P., Zimmet H., Billah B., Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010, 170:507-514.
64. Mueller C., Breidthardt T., Laule-Kilian K., Christ M., Perruchoud A.P. The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly 2007, 137:4-12.
65. Logeart D., Thabut G., Jourdain P., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. JAm Coll Cardiol 2004, 43:635-641.
66. Salah K., Kok W.E., Eurlings L.W., et al. Anovel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score. Heart 2014, 100:115-125.
67. Ledwidge M., Gallagher J., Conlon C., et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013, 310:66-74.
68. Huelsmann M., Neuhold S., Resl M., et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. JAm Coll Cardiol 2013, 62:1365-1372.
69. Smith G.L., Lichtman J.H., Bracken M.B., et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. JAm Coll Cardiol 2006, 47:1987-1996.
70. Patel P.C., Ayers C.R., Murphy S.A., et al. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail 2009, 2:98-104.
71. van Deursen V.M., Damman K., Voors A.A., et al. Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ Heart Fail 2014, 7:35-42.
72. Latini R., Masson S., Anand I.S., et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 116:1242-1249.
73. Gravning J., Askevold E.T., Nymo S.H., et al. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. Circ Heart Fail 2014, 7:96-103.
74. Masson S., Anand I., Favero C., et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 2012, 125:280-288.
75. Pascual-Figal D.A., Manzano-Fernandez S., Boronat M., et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011, 13:718-725.
76. Weinberg E.O., Shimpo M., Hurwitz S., et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107:721-726.
77. Weinberg E.O. ST2 protein in heart disease: from discovery to mechanisms and prognostic value. Biomark Med 2009, 3:495-511.
78. Januzzi J.L. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. JCardiovasc Transl Res 2013, 6:493-500.
79. Bartunek J., Delrue L., Van D.F., et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. JAm Coll Cardiol 2008, 52:2166-2174.
80. Januzzi J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. JAm Coll Cardiol 2007, 50:607-613.
81. Wu A.H., Wians F., Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J 2013, 165:995-999.
82. Bayes-Genis A., Zamora E., de Antonio M., et al. Soluble ST2 serum concentration and renal function in heart failure. JCard Fail 2013, 19:768-775.
83. Basuray A., French B., Ky B., et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 2014, 129:2380-2387.
84. Bayes-Genis A., de Antonio M., Vila J., et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. JAm Coll Cardiol 2014, 63:158-166.
85. Edelmann F., Wachter R., Schmidt A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013, 309:781-791.
86. Pitt B., Pfeffer M.A., Assmann S.F., et al. Spironolactone for heart failure with preserved ejection fraction. NEngl J Med 2014, 370:1383-1392.
87. Cruden N.L., Fox K.A., Ludlam C.A., Johnston N.R., Newby D.E. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension 2004, 44:913-918.
88. Maric C., Zheng W., Walther T. Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase. Nephron Physiol 2006, 103:149-156.
89. Rademaker M.T., Charles C.J., Espiner E.A., et al. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II. JCardiovasc Pharmacol 1998, 31:116-125.
90. Kostis J.B., Packer M., Black H.R., et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004, 17:103-111.
91. Packer M., Califf R.M., Konstam M.A., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002, 106:920-926.
92. McMurray J.J., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. NEngl J Med 2014, 371:993-1004.